Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DoorDash Inc (DASH) vs Smith & Nephew plc (SNN) Price & Performance

DoorDash IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

DoorDash Inc vs Smith & Nephew plc — how do they compare? DoorDash Inc trades at $212.02 (market cap $90.93B), while Smith & Nephew plc trades at $30.05 (market cap $12.50B). The key difference: DoorDash Inc is far larger — about 7.3× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.64% dividend while DoorDash Inc pays none. Which is the better fit depends on your goals.

DASHSNN
Market Cap
$90.93B$12.50B
Sector
Consumer CyclicalHealth
52-Week High
$281.74$38.70
52-Week Low
$146.60$28.73
Enterprise Value
$88.89B$15.53B
Dividend Yield
2.64%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DoorDash Inc

DoorDash (DASH) trades at $216.26, up 1.41% with strong technical momentum above key support levels. The company demonstrates robust revenue growth, with Q2 2026 revenue up 36% YoY to $4.45B, though earnings missed estimates due to higher R&D costs. Analyst sentiment remains overwhelmingly positive with 75.68% buy ratings and a $247.41 consensus price target, representing 14.4% upside potential from current levels.

DoorDash's expansion into grocery, retail, and international markets supports growth, but elevated valuation multiples (P/E 113.23) and intense competition present risks. The stock's technical strength and fundamental growth trajectory suggest continued upside, though investors should monitor execution on profitability targets and competitive pressures in the delivery space.

Smith & Nephew plc

SNN trades at $30.11, up 1.41% in the last session. Technical indicators are bearish, with moving averages signaling a downtrend. Fundamentally, the company reported Q2 2026 revenue growth of 1.6% but cut its full-year outlook to 4% from 6% due to weakness in U.S. Orthopaedics and Advanced Wound Bioactives (MarketBeat, 2026-08-09). Recent product launches include the LYNX COBLATION Wand and CORI XT robotics platform, supporting innovation in medical technology.

The outlook is mixed: strong profitability margins and recent earnings beats offer support, but lowered guidance and bearish technicals pose near-term headwinds. Risks include execution challenges in key markets, while analyst consensus leans Hold, reflecting cautious optimism amid growth uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About DoorDash Inc

Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).

Read more on DASH

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN